Okyo Pharma Limited (OKYO.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in thousands)
| 03-2026 | 09-2025 | 03-2025 | 09-2024 | 03-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 14,594 | 4,220 | 1,561 | 987 | 827 |
| Marketable Securities | 6,000 | N/A | N/A | N/A | N/A |
| Receivables | 171 | 23 | 1,889 | 1,516 | 581 |
| TOTAL | $20,970 | $4,643 | $3,675 | $2,827 | $1,538 |
| Non-Current Assets | |||||
| PPE Net | 6 | 1 | 2 | 2 | 3 |
| TOTAL | $6 | $1 | $2 | $2 | $3 |
| Total Assets | $20,976 | $4,644 | $3,677 | $2,829 | $1,541 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 186 | N/A | 2 | N/A |
| Accounts payable and accrued liabilities | 7,136 | 7,111 | 7,900 | 8,713 | 6,128 |
| Accrued Expenses | 1,239 | 529 | 379 | 894 | 830 |
| TOTAL | $8,641 | $8,059 | $9,227 | $10,054 | $7,421 |
| Non-Current Liabilities | |||||
| TOTAL | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $8,641 | $8,059 | $9,227 | $10,054 | $7,421 |
| Shareholders' Equity | |||||
| Common Shares | 173,559 | 151,225 | 146,717 | 144,050 | 143,113 |
| Retained earnings | -151,972 | -145,609 | -143,025 | -145,203 | -142,523 |
| Other shareholders' equity | -9,252 | -9,032 | -9,242 | -6,073 | -6,469 |
| TOTAL | $12,335 | $-3,415 | $-5,550 | $-7,226 | $-5,880 |
| Total Liabilities And Equity | $20,976 | $4,644 | $3,677 | $2,829 | $1,541 |